Analysis BioNTechâs May Marathon: Earnings, a Shareholder Vote, and a Rivalâs Data Test the Oncology Pivot
For a company sitting on nearly âŹ17 billion in cash, BioNTech is navigating a remarkably precarious moment. The German biotech enters a packed May calendar with a radical restructuring plan,...